Jana Markova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jana Markova has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Heidi Mocikova
Department of Hematology, Fakultni nemocnice Kralovske Vinohrady and 3rd Faculty of Medicine, Charles University, Prague, Czech Republic
2 shared publications - Michal Hajdúk
Department of Psychology, Faculty of Arts, Comenius University in Bratislava
2 shared publications - Zsolt Cséfalvay
Faculty of Paedagogics Comeniu University, Department of communication, Bratislava, Slovak Republic
2 shared publications A.S. Jacob
Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne; German Hodgkin Study Group (GHSG), Cologne
1 shared publicationAlice Kušnírová
II. neurologická klinika Lekárskej fakulty Univerzity Komenského a Univerzitnej nemocnice, Bratislava, Nemocnica akad. L. Dérera
1 shared publication- Alice Sýkorová
Charles University and University Hospital Hradec Králové
1 shared publication
Latest Publications
- Open Access
- 5 December 2023
- Published by Elsevier in Annals of Oncology
- Vol. 35 (3) , 276-284
Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin’s lymphoma: results from the randomized international GHSG HD18 trial
- 5 December 2023
- Published by Elsevier in Annals of Oncology
- Vol. 35 (3) , 276-284
Open AccessImpact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin’s lymphoma: results from the randomized international GHSG HD18 trial
- Open Access
- 15 March 2022
- Published by North Atlantic University Union (NAUN) in International Journal of Economics and Statistics
- Vol. 10, 128-132
The Impact of Tax Reform in Slovakia on Creation of Profit in Companies
This paper examines the relationship of tax policy of state and the creation of profit in selected tax subjects. The aim of paper is in the context of more than a decennial development of economy of Slovakia to verify and to the numerical rich material to show whether the tax reform in 2004, which was declared as pro-business oriented by then government, significantly affected the financial results of companies.
- 15 March 2022
- Published by North Atlantic University Union (NAUN) in International Journal of Economics and Statistics
- Vol. 10, 128-132
Open AccessThe Impact of Tax Reform in Slovakia on Creation of Profit in Companies
This paper examines the relationship of tax policy of state and the creation of profit in selected tax subjects. The aim of paper is in the context of more than a decennial development of economy of Slovakia to verify and to the numerical rich material to show whether the tax reform in 2004, which was declared as pro-business oriented by then government, significantly affected the financial results of companies.
- Open Access
- 5 November 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (Supplement) , 4539
Is It Better to Start Treatment with ABVD and Continue with PET2-Adapted Approach or Should We Use 2 Cycles of Beacopp Escalated and 2 Cycles of ABVD and Irradiation in Early Unfavorable Hodgkin Lymphoma?
Introduction. EORTC H10 trial confirmed better selection of patients who needed reduced or more intensive treatment using PET response after 2 cycles of ABVD in early stages of classical Hodgkin lymphoma (cHL). GHSG HD17 showed that radiotherapy can be safely omitted in PET4-negative early unfavorable HL treated with 2 cycles of BEACOPP escalated plus 2 cycles of ABVD (2+2 chemotherapy). We compared PET2-adapted approach including 30Gy involved-node radiotherapy (INRT) with 2+2 chemotherapy followed by 30 Gy INRT (or involved-field radiotherapy, IFRT) regardless of interim PET in patients with early unfavorable cHL assessed according to the GHSG risk factors. Methods. Overall 243 patients with early unfavorable cHL (aged 18-60 years) prospectively observed in the Czech Hodgkin lymphoma study group registry between 2003-2020 were analyzed. Patients in clinical stage IIB with massive mediastinal tumor and/or with extranodal disease were not included into this analysis as they were treated with BEACOPP escalated only. Chemotherapy 2+2+30 Gy INRT/IFRT received 213 patients. Overall 30 patients were treated with PET2-adapted approach: 29 PET2-negative patients received 4 cycles of ABVD and 30 Gy INRT and one PET2-positive patient was treated with 2 cycles of ABVD plus 2 cycles of BEACOPP escalated and 30 Gy INRT. Results. Median age at the time of cHL diagnosis was 32 (range 18-59) years. Median follow-up was longer in the 2+2+INRT/IFRT group (91.3, range 6.2-211.2) months when compared to the PET2-adapted approach (19.4, range 6.4-90.4) months. The estimated 2-year progression-free survival (PFS) did not differ in both groups (100% [95% CI 100-100] both), however, the estimated 5-year PFS was significantly better in the 2+2+INRT/IFRT group (99.5% [95% CI 98.5-100]) in comparison to PET2-adapted treatment (75.0% [95% CI 32.5-100]), p<0.001. The estimated 5-year overall survival was comparable in both groups (2+2+INRT/IFRT: 99.5% [95% CI 98.5-100]; PET2-guided treatment: 100% [95% CI 100-100]). Hematological toxicity was reported in most of the patients in both groups. Grade 3 non-hematological toxicity occured in 3 patients in the 2+2+INRT/IFRT approach (2 infections, 1 deep vein thrombosis). Conclusion. This retrospective analysis indicates that 2+2+INRT/IFRT is more effective in the long-term disease control, but there is no difference in overall survival in both groups. The current approach includes 2+2 chemotherapy and INRT is added in PET4-positive patients. This work was supported by the Research project Q 28 Progres awarded by the Third Faculty of Medicine of Charles University in Prague in the Czech Republic.
- 5 November 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (Supplement) , 4539
Open AccessIs It Better to Start Treatment with ABVD and Continue with PET2-Adapted Approach or Should We Use 2 Cycles of Beacopp Escalated and 2 Cycles of ABVD and Irradiation in Early Unfavorable Hodgkin Lymphoma?
Introduction. EORTC H10 trial confirmed better selection of patients who needed reduced or more intensive treatment using PET response after 2 cycles of ABVD in early stages of classical Hodgkin lymphoma (cHL). GHSG HD17 showed that radiotherapy can be safely omitted in PET4-negative early unfavorable HL treated with 2 cycles of BEACOPP escalated plus 2 cycles of ABVD (2+2 chemotherapy). We compared PET2-adapted approach including 30Gy involved-node radiotherapy (INRT) with 2+2 chemotherapy followed by 30 Gy INRT (or involved-field radiotherapy, IFRT) regardless of interim PET in patients with early unfavorable cHL assessed according to the GHSG risk factors. Methods. Overall 243 patients with early unfavorable cHL (aged 18-60 years) prospectively observed in the Czech Hodgkin lymphoma study group registry between 2003-2020 were analyzed. Patients in clinical stage IIB with massive mediastinal tumor and/or with extranodal disease were not included into this analysis as they were treated with BEACOPP escalated only. Chemotherapy 2+2+30 Gy INRT/IFRT received 213 patients. Overall 30 patients were treated with PET2-adapted approach: 29 PET2-negative patients received 4 cycles of ABVD and 30 Gy INRT and one PET2-positive patient was treated with 2 cycles of ABVD plus 2 cycles of BEACOPP escalated and 30 Gy INRT. Results. Median age at the time of cHL diagnosis was 32 (range 18-59) years. Median follow-up was longer in the 2+2+INRT/IFRT group (91.3, range 6.2-211.2) months when compared to the PET2-adapted approach (19.4, range 6.4-90.4) months. The estimated 2-year progression-free survival (PFS) did not differ in both groups (100% [95% CI 100-100] both), however, the estimated 5-year PFS was significantly better in the 2+2+INRT/IFRT group (99.5% [95% CI 98.5-100]) in comparison to PET2-adapted treatment (75.0% [95% CI 32.5-100]), p<0.001. The estimated 5-year overall survival was comparable in both groups (2+2+INRT/IFRT: 99.5% [95% CI 98.5-100]; PET2-guided treatment: 100% [95% CI 100-100]). Hematological toxicity was reported in most of the patients in both groups. Grade 3 non-hematological toxicity occured in 3 patients in the 2+2+INRT/IFRT approach (2 infections, 1 deep vein thrombosis). Conclusion. This retrospective analysis indicates that 2+2+INRT/IFRT is more effective in the long-term disease control, but there is no difference in overall survival in both groups. The current approach includes 2+2 chemotherapy and INRT is added in PET4-positive patients. This work was supported by the Research project Q 28 Progres awarded by the Third Faculty of Medicine of Charles University in Prague in the Czech Republic.
- 12 February 2019
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 29, S453-S454
Neurocognitive disorders and language: The impact of cognitive decline and neuropsychiatric symptoms on the language performance
- 12 February 2019
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 29, S453-S454
Neurocognitive disorders and language: The impact of cognitive decline and neuropsychiatric symptoms on the language performance
- 31 January 2018
- Published by Care Comm in Česká a slovenská neurologie a neurochirurgie
- Vol. 81/114 (1) , 60-65
Sentence comprehension in Slovak-speaking patients with Parkinson disease
- 31 January 2018
- Published by Care Comm in Česká a slovenská neurologie a neurochirurgie
- Vol. 81/114 (1) , 60-65
Sentence comprehension in Slovak-speaking patients with Parkinson disease
- Open Access
- 1 March 2015
- Published by S. Karger AG in Acta Haematologica
- Vol. 134 (3) , 187-192
Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?
Background: Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma showing strong CD20 expression. The role of rituximab in treating NLPHL still needs clarification. Methods: We retrospectively reviewed the outcome of 23 patients with NLPHL treated with rituximab alone or in combination with chemotherapy and/or radiotherapy as part of their first- or second-line treatment. Results: The median follow-up of the whole group was 67 months, and all patients remained alive. Twenty-two patients achieved complete remission after rituximab-based therapy, and one of them relapsed 32 months after treatment. One patient treated with rituximab alone achieved partial remission and progressed 22 months after treatment. Conclusion: The prognosis of NLPHL is excellent. Rituximab combined with chemotherapy and/or radiotherapy appears to prevent disease progression/relapse.
- 1 March 2015
- Published by S. Karger AG in Acta Haematologica
- Vol. 134 (3) , 187-192
Open AccessCan Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?
Background: Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma showing strong CD20 expression. The role of rituximab in treating NLPHL still needs clarification. Methods: We retrospectively reviewed the outcome of 23 patients with NLPHL treated with rituximab alone or in combination with chemotherapy and/or radiotherapy as part of their first- or second-line treatment. Results: The median follow-up of the whole group was 67 months, and all patients remained alive. Twenty-two patients achieved complete remission after rituximab-based therapy, and one of them relapsed 32 months after treatment. One patient treated with rituximab alone achieved partial remission and progressed 22 months after treatment. Conclusion: The prognosis of NLPHL is excellent. Rituximab combined with chemotherapy and/or radiotherapy appears to prevent disease progression/relapse.